EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1823-1827

  Hachem, Ray ^a   Bahna, Paul ^a   Hanna, Hend ^a   Stephens, L Clifton ^a   Raad, Issam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; ECHINOCANDIN; EDETIC ACID; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; LUNG ASPERGILLOSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CALCIUM; COLONY COUNT, MICROBIAL; CONFIDENCE INTERVALS; CREATININE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; EDETIC ACID; LUNG DISEASES, FUNGAL; MALE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33646445592     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1823-1827.2006     Document Type: Article

References (19)

1. Andriole, V. T. 1996. Aspergillus infections: problems in diagnosis and treatment. Infect. Agents Dis. 54:47-54.
2. Andriole, V. T. 1993. Infections with Aspergillus species. Clin. Infect. Dis. 17:5481-5486.
3. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
4. Graybill, J. R., R. Bocanegra, G. M. Gonzalez, and L. K. Najvar. 2003. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother. 52:656-662.
5. Groll, A. H., P. M. Shah, M. Mentzel, G. Schneider, G. Just-Nuebling, and K. Huebner. 1996. Trends in the postmortem epidemiology of fungal infections at a university hospital. J. Infect. 33:23-32.
6. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, M. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415,
7. Kontoyiannis, D. P., R. Hachem, R. E. Lewis, G. A. Rivero, H. A. Torres, J. Thornby, R. Champlin, H. Kantarjian, G. P. Bodey, and I. I. Raad. 2003 Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-299.
8. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh for the Caspofungin Salvage Aspergillosis Study Group. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.
9. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002, Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.
10. Martin, M. T., J. Gavalda, P. Lopez, X. Gomis, J. L. Ramirez, D. Rodriguez, O. Len, Q. Jordano, I. Ruiz, M. Rosal, B. Almirante, and A. Pahissa. 2003. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J. Antimicrob. Chemother. 52:1032-1034.
11. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard. NCCLS document M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. 11a. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
13. Patterson, T. F., W. R. Kirkpatrick, M. White, J. W. Hiemenz, J. R. Wingard, B. Dupont, M. G. Rinaldi, D. A. Stevens, J. R. Graybill, et al. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79:250-260.
14. Roberts, J., K. Schock, S. Marino, and V. T. Andriole. 2000. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 44:3381-3388.
15. Sanchez-Fructuoso, A. I., J. Blanco, M. Cano, L. Ortega, M. Arroyo, C. Fernandez, D. Prats, and A. Barrientos. 2002. Experimental lead nephropathy: treatment with calcium disodium ethylenediaminetetraacetate. Am. J. Kidney Dis. 40:59-67.
16. Sen, B. H., G. Akdeniz, and A. Denizci. 2000. The effect of ethylenediamine-tetraacetic acid on Candida albicans. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 90:651-655.
17. Van Etten, E. W. M., L. E. T. Stearne-Cullen, M. T. Ten Kate, and I. A. J. M. Bakker-Woudenberg. 2000. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrob. Agents Chemother. 44:540-545.
18. Walsh, T. J., P. Pappas, D. J. Winston, H. M. Lazarus, F. Petrsen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, M. Schuster, A. Reboli, J. Wingard, C. Arndt, J. Reinhardt, S. Hadley, R. Finberg, M. Laverdiere, J. Perfect, G. Garber, G. Fioritoni, E. Anaissie, and J. Lee for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.
19. Wei, G.-X., and L. A. Bobek. 2005. Human salivary mucin MUC7 12-Mer-L and 12-Mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells. Antimicrob. Agents Chemother. 49:2336-2342.